From: Carolyn Balkenhol <cbalkenhol@theranos.com>
Sent: Monday, May 3, 2010 6:05 PM
To: Victoria Sung <VSung@celgene.com>
Subject: RE: Agenda for May 7 Face-to-face
Attach: 100503 Celgene-Theranos F2F Agenda (updated by Theranos).doc

---

Vicki,

Here's our very slightly modified version. I added Daniel Young and Sunny Balwani to the meeting – and added one agenda item at the end, if you all have time to get to it.

Thanks so much for drafting this. It was very helpful, and I hope our changes are acceptable.

Carolyn

From: Victoria Sung [mailto:VSung@celgene.com]
Sent: Thursday, April 29, 2010 11:13 AM
To: Elizabeth Holmes; Gary Frenzel; Surekha Gangakhedkar
Cc: Carolyn Balkenhol
Subject: Agenda for May 7 Face-to-face

Hi everyone,
We're looking forward to meeting with you next week and thought it might be useful to set an agenda. I've attached a draft which includes who will attend from Celgene (in-person and by phone) and would appreciate if you would do the same for Theranos attendees. I welcome your suggestions with regard to agenda items; what is currently listed is what we have identified as high priority from our end. The first agenda item, "Clinical trial details, sample collection, cartridge logistics" is of most interest to the clinical and operational teams, which is why it's listed first…many folks dialing in will likely only join for this portion of the meeting).

I don't know how much time you need to present an update on your assay development efforts, so please also feel free to change the times allocated to each agenda item if necessary. I understand that Ariel and Steve will be visiting you next week as well, so hopefully contract issues will be resolved by the time we meet. If necessary, however, we can still put together our own PD Biomarker SOW.

Would you please send me your edits by next Tuesday? I will then incorporate all changes and circulate a final version of the agenda.

Thank you and regards,
Vicki

Victoria Sung, Ph.D.
Translational Medicine
Celgene Corporation
1500 Owens St. Suite 600
San Francisco, CA 94158
Tel: 415-839-7046
Fax: 415-839-7011

****
THIS ELECTRONIC MAIL MESSAGE AND ANY ATTACHMENT IS
CONFIDENTIAL AND MAY CONTAIN LEGALLY PRIVILEGED
INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL
OR INDIVIDUALS NAMED ABOVE.
If the reader is not the intended recipient, or the
employee or agent responsible to deliver it to the
intended recipient, you are hereby notified that any
dissemination, distribution or copying of this
communication is strictly prohibited. If you have
received this communication in error, please reply to the
sender to notify us of the error and delete the original
message. Thank You.
****

Celgene – Theranos Face-to-Face Agenda
ACE-011 Project
5/7/10 (8:30 am Pacific, 11:30 pm Eastern)

Attendees

Celgene:
Lea Aukerman, PhD, Senior Director, Translational Development
Sharianne Louie, MS, Manager, Translational Development
Vicki Sung, PhD, Senior Scientist, Translational Development

By phone:
Will Smith, MD, Director, Clinical R&D
Lisa Serme, Manager, Clinical Operations
Hem (Nalini) Singh, Senior Scientist, Clinical Research
Peter Bryan, Assoc. Director, DMPK

Theranos:
Sunny Balwani, Vice Chairman
Gary Frenzel, VP Assay Systems
Surekha Gangakhedkar, Team Manager, Assay Systems
Elizabeth Holmes, CEO
Daniel Young, Director, Theranos Operating System and Computational Biosciences

TC info

US	moderator	participant
1-866-546-3377	1822016	182201

Subject	Presenter	Time
Introductions	All	5 minutes

Clinical trial details, sample collection, cartridge logistics
• Trial: part 1 vs. part 2 and timeline
• Sample collection
  ○ Single draw for all assays?
  ○ What is the shortest expiry time for analytes at ambient temperature?
• Cartridge logistics:
  ○ How many wells required for each analyte including controls?
  ○ Do we need a dilution series for certain analytes?
  ○ Bottom line: how many cartridges are required for PK and all PD markers or for PK and priority PD markers?
• Clinical site staff challenges for processing samples on multiple cartridges (site training, time to load/run cartridges, need for multiple machines to be deployed to each site)
	• Celgene
	• Theranos
		30 minutes

Assay Update
• Current assay development status
  ○ Which assays will be ready for Part 1?
  ○ Which assays will be ready for Part 2?
• Are the "low priority" biomarkers necessary for modeling purposes? If not, can they be optional (ACM data can be made available to Theranos)?
	Theranos	1 hour

Assay Validation Plan / Development Timeline • What samples will be used for assay validation? ○ Plasma vs. whole blood from renal patients on dialysis • Validation plan/timeline/TC updates • Central lab assays • Access for Celgene consultant	All	1 hour
Web portal and device customization • Blinded vs. unblinded data • Information to be entered via device	All	30 minutes
Any other issues		Time remaining